BioCentury | Jan 10, 2020
Clinical News

Gene therapy readout helps Ultragenyx rebound

...to $53.96. Ultragenyx shares had taken a hit after a September readout for gene therapy DTX401...
BioCentury | Sep 4, 2019
Clinical News

Gene therapy data weigh on Ultragenyx shares

...on Wednesday as investors digested additional data from a Phase I/II trial of gene therapy DTX401...
...dose is optimal for a Phase III study. Patients in the second cohort received a DTX401...
...for the Study of Inborn Errors of Metabolism (SSIEM) symposium in Rotterdam. Stephen Hansen, Associate Editor DTX401, DTX401 AAV G6Pase Ultragenyx...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...data are expected in mid-2019 from both DTX301 to treat ornithine transcarbamylase deficiency (OTCD) and DTX401...
BioCentury | Oct 2, 2017
Company News

RegenxBio won't match Ultragenyx's Dimension offer

...on Monday. Dimension dipped $0.10 to $5.90, and RegenxBio was up $0.55 to $33.50. Elizabeth S. Eaton burosumab DTX301 DTX401 Dimension...
BioCentury | Sep 22, 2017
Company News

Ultragenyx counters RegenxBio with bid for Dimension

...cells. Dimension plans to submit an IND early next year for its next lead candidate DTX401...
...Pharmaceutical Inc. (NASDAQ:RARE), Novato, Calif. RegenxBio Inc. (NASDAQ:RGNX), Rockville, Md. Business: Gene/cell therapy, Endocrine/Metabolic Elizabeth S. Eaton burosumab DTX301 DTX401 KRN23 Dimension...
BioCentury | Sep 18, 2017
Company News

Ultragenyx counters RegenxBio with bid for Dimension

...cells. Dimension plans to submit an IND early next year for its next lead candidate DTX401...
...RegenxBio added $1.55 to $29.80, and Ultragenyx slipped $2.24 to $52.99 on Monday. Elizabeth S. Eaton DTX301 DTX401 Dimension...
BioCentury | Sep 1, 2017
Company News

RegenxBio acquiring gene therapy play Dimension

...the deal to close by year end. RegenxBio will gain Dimension's lead products DTX301 and DTX401...
...I/II testing to treat OTC deficiency. An IND submission is slated for early 2018 for DTX401...
...Therapeutics Inc. (NASDAQ:DMTX), Cambridge, Mass. RegenxBio Inc. (NASDAQ:RGNX), Rockville, Md. Business: Gene/Cell therapy, Endocrine/Metabolic, Hematology Chris Lieu DTX101 DTX201 DTX301 DTX401 Bayer...
BioCentury | Aug 25, 2017
Company News

RegenxBio acquiring gene therapy play Dimension

...the deal to close by year end. RegenxBio will gain Dimension's lead products DTX301 and DTX401...
...I/II testing to treat OTC deficiency. An IND submission is slated for early 2018 for DTX401...
...license. On Friday, RegenxBio shed $0.65 to $21.05, and Dimension jumped $1.95 (163%) to $3.15. Chris Lieu DTX101 DTX201 DTX301 DTX401 Bayer...
BioCentury | May 25, 2015
Emerging Company Profile

Dimension's intentions

...are in the clinic for the disorder, which Jenkins said affects about 10,000 patients worldwide. DTX401...
Items per page:
1 - 9 of 9